---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-115955"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2024-10-21T23:59:59+00:00"
generated_at: "2026-05-30T12:24:06.621519+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences receives Nasdaq deficiency notices for bid price and stockholders' equity; intends to appeal

## Summary
- Nasdaq notified REVB of non-compliance with $1.00 minimum bid price rule as of October 16, 2024.
- Company not eligible for 180-day cure period due to reverse stock splits exceeding 250:1 cumulative ratio over two years.
- Also cited for stockholders' equity deficiency (rule 5550(b)(1)), but company believes it satisfied requirement as of Sept 30, 2024 via Q3 financing.
- Company will request a hearing before Nasdaq hearings panel to stay any suspension or delisting pending appeal.
- Trading of common stock (REVB) and warrants (REVBW) continues on Nasdaq Capital Market for now.

## SEC filing metadata
- accession: 0000950170-24-115955
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2024-10-21T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017024115955/0000950170-24-115955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017024115955/revb-20241016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-115955
- JSON: https://secwatch.observer/filing/0000950170-24-115955.json
- Plain text: https://secwatch.observer/filing/0000950170-24-115955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.